JAK1 and graft versus host disease: The development of novel GVHD prophylaxis such as ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor (125, 126), and the use of biomarker panels to predict outcomes and direct therapy of GVHD (127) may further improve the safety of HCT and expand its applicability for SCD.